Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: SABMiller Rises But FTSE 100 Hit By China Data

Tue, 13th Oct 2015 07:39

LONDON (Alliance News) - UK shares opened lower, weighed down by weak economic data from China, while SABMiller led the gainers in London after it agreed to GBP71.28 billion takeover by brewing rival Anheuser-Busch InBev.

AB InBev lifted its offer to GBP44.00 per share, and its smaller rival said it will be willing to recommend a bid at that price to its shareholders. The previous offer valued SABMiller at GBP43.50 per share.

In the event of an offer, AB InBev said it would agree to a "best efforts" commitment to secure regulatory approvals required for the deal to go through. A USD3 billion break fee would be paid to SABMiller in the event that an agreed deal fell through due to a failure to obtain regulatory clearances or the approval of AB InBev shareholders.

In addition, SABMiller shareholders will be entitled to any dividends declared or paid in the period to September 30 or March 31 ahead of completion of a possible deal. Dividends could amount to a maximum of USD1.22 per share over the two periods.

No formal offer has been made. AB InBev now has until 1700 BST on October 28 to decide whether to make an firm offer or walk away.

The FTSE 100 index was down 0.5% at 6,337.35, the FTSE 250 was down 0.5% at 16,902.43, and the AIM All-Share was down 0.1% at 734.29. In Europe, the French CAC 40 index and the German DAX 30 were down 1.1% and 0.6%, respectively.

Asian stocks also were mixed on Tuesday. The Japanese Nikkei 225 index ended down 1.1%, reopening after a holiday on Monday. In China, the Hang Seng index in Hong Kong was off 0.6%, but the Shanghai Composite closed up 0.2%, following weak economic data from the Asian giant.

China's exports declined at a moderate pace in September as the devaluation of yuan helped it from falling sharply amid weak global demand. At the same time, imports plunged due to a drop in commodity prices and subdued domestic demand.

On a yearly basis, exports slid 1.1% in September, compared to a 5.5% decline seen in August, the General Administration of Customs reported Tuesday. Economists had forecast it to drop at a faster pace of 6.3%.

Meanwhile, imports logged a sharp 17.7% contraction after falling 13.8% a month ago. This was the eleventh straight annual decline in imports. Imports were expected to decline 15%.

The trade surplus totalled USD60.34 billion, bigger than a USD48.2 billion surplus expected by economists.

"The deterioration in recent Chinese trade data has reinforced concerns about the health of the Chinese economy as sliding commodity prices and weak consumer demand has seen both imports and exports slow much more than expected in the months since June," said CMC Markets chief market analyst Michael Hewson.

"The numbers also suggest that next week?s gross domestic product could well come in well below the 7% threshold targeted by Chinese officials as their GDP target," Hewson added.

Outside China, the German consumer price index came in line with economists expectations. Month-on-month, Germany's CPI fell 0.2%, matching an similar 0.2% decline seen in August. Meanwhile, on a yearly basis, inflation came in flat at 0%.

Still in the economic calendar, the ZEW surveys for Germany and the EU are due at 1000 BST. Meanwhile, the consumer, retail and producer price indices from the UK are expected at 0930 BST, while at the same time the Bank of England releases its credit conditions survey. In the US, the Redbook index is due at 1355 BST.

"Last month saw the [UK] headline CPI rate, which has fluctuated between 0.1% and -0.1% year-on-year since February, fall back by 0.1 percentage point to 0.0%, partly on the back of weaker petrol prices and a 0.2 percentage points drop in core inflation to 1.0%," said Jonathan Thomas, senior economist at Lloyds Bank.

"The initial impacts from a fall in trade-weighted sterling and pickup in oil prices since mid-August are set to be countered by a further dip in forecourt prices and cuts to domestic gas tariffs in September. Thus we expect both the headline and core rates to remain unchanged," Thomas added.

On the London Stock Exchange, Royal Mail was the top faller in the FTSE 100, down 4.5%, after the UK government said it has sold the majority of its 14% stake in the group for around GBP591.0 million under an accelerated bookbuilding process that was announced late Monday.

The government said it has sold a 13% stake in the company, comprised of around 130.0 million shares, at a placing price of 455.0 pence per share, generating proceeds of GBP591.1 million.

The government owned a 14% stake in Royal Mail, leaving it with a 1% shareholding after the placing. That remaining 1% stake, comprised of around 10.0 million shares, will be "gifted" to Royal Mail employees in the UK, marking the government's final disposal of shares.

Concerns about China's economy health were hitting London-listed mining stocks. Glencore was down 3.5%, Anglo American down 2.9% and BHP Billiton down 2.0%. Among mid-caps, KAZ Minerals was down 5.8% and Vedanta Resources was off 1.7%.

Going in the opposite direction was GlaxoSmithKline, up 1.0%, after JPMorgan upgraded the drugmaker to Neutral from Underweight.

In the FTSE 250, Bellway was the top performer, up 3.9%. The housebuilder said it should be able to grow volumes by up to 10% in its current financial year, as the group reported a 44% jump in pretax profit in its most recent financial year and raised its dividend.

In a statement, Bellway said pretax profit amounted to GBP354.2 million in the year ended July 31, compared with GBP246.0 million in the prior year, as revenue swelled to GBP1.77 billion from GBP1.48 billion. The housebuilder lifted its full-year dividend per share by 48% to 77.0 pence from 52.0p.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.